Conatus Pharmaceuticals Inc. (CNAT): Bullish Rating Reiterated

CNAT – H.C. Wainwright & Co. reiterates Buy rating, $17 PT. This price target represents a 147.09% upside over the stock’s previous closing price of $6.88.


Update: As of Dec. 10, 2018, this bullish analyst call has returned -78.20%.


Key Facts Surrounding This News Item


  • CNAT had a POWR Rating of B (Buy) coming into today.
  • CNAT was 18.46% above its 10-Day Moving Average coming into today.
  • CNAT was 25.87% above its 20-Day Moving Average coming into today.
  • CNAT was 33.33% above its 50-Day Moving Average coming into today.
  • CNAT was 43.30% above its 100-Day Moving Average coming into today.
  • CNAT was 33.12% above its 200-Day Moving Average coming into today.
  • CNAT had returned +48.92% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Conatus Pharmaceuticals Inc. (CNAT)


Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company was founded in 2005 and is based in San Diego, California. View our full CNAT ticker page with ratings, news, and more.

CNAT at a Glance

CNAT Current POWR Rating™
Overall POWR Rating™
CNAT Current Price $1.50 12.28%
More CNAT Ratings, Data, and News

CNAT Price Reaction

The day of this event (Mar. 8, 2018)
CNAT Closing Price$7.50 9.01%
CNAT Volume1,639,400
179.86% from avg
Leading up to this event
CNAT 1-mo return35.70%
After this event
CNAT 1-day return5.36%
CNAT 3-day return0.58%
CNAT 5-day return9.90%

CNAT Price Chart


The Top Stocks For 2019

More Conatus Pharmaceuticals Inc. (CNAT) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CNAT News
Page generated in 0.8483 seconds.